Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis

NYSE:DNA - US37611X2099 - Common Stock

12.35 USD
-0.43 (-3.36%)
Last: 8/27/2025, 8:04:00 PM
12.5 USD
+0.15 (+1.21%)
Pre-Market: 8/28/2025, 8:29:14 AM
Fundamental Rating

4

DNA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 84 industry peers in the Chemicals industry. DNA has a great financial health rating, but its profitability evaluates not so good. DNA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DNA has reported negative net income.
In the past year DNA has reported a negative cash flow from operations.
In the past 5 years DNA always reported negative net income.
In the past 5 years DNA always reported negative operating cash flow.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -500M -1B -1.5B -2B

1.2 Ratios

DNA's Return On Assets of -25.60% is on the low side compared to the rest of the industry. DNA is outperformed by 86.90% of its industry peers.
The Return On Equity of DNA (-51.42%) is worse than 82.14% of its industry peers.
Industry RankSector Rank
ROA -25.6%
ROE -51.42%
ROIC N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of DNA (78.99%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of DNA has declined.
DNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DNA has been increased compared to 1 year ago.
Compared to 5 years ago, DNA has less shares outstanding
DNA has a better debt/assets ratio than last year.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of -6.35, we must say that DNA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DNA (-6.35) is worse than 86.90% of its industry peers.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.35
ROIC/WACCN/A
WACC8.89%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 5.41 indicates that DNA has no problem at all paying its short term obligations.
DNA has a Current ratio of 5.41. This is amongst the best in the industry. DNA outperforms 94.05% of its industry peers.
DNA has a Quick Ratio of 5.41. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.41, DNA belongs to the best of the industry, outperforming 94.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.41
Quick Ratio 5.41
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.95% over the past year.
Looking at the last year, DNA shows a very strong growth in Revenue. The Revenue has grown by 25.24%.
The Revenue has been growing by 33.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%

3.2 Future

The Earnings Per Share is expected to grow by 14.86% on average over the next years. This is quite good.
Based on estimates for the next years, DNA will show a very strong growth in Revenue. The Revenue will grow by 46.59% on average per year.
EPS Next Y40.12%
EPS Next 2Y20.9%
EPS Next 3Y17.78%
EPS Next 5Y14.86%
Revenue Next Year-22.09%
Revenue Next 2Y-5.87%
Revenue Next 3Y-0.63%
Revenue Next 5Y46.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNA. In the last year negative earnings were reported.
Also next year DNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as DNA's earnings are expected to grow with 17.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.9%
EPS Next 3Y17.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (8/27/2025, 8:04:00 PM)

Premarket: 12.5 +0.15 (+1.21%)

12.35

-0.43 (-3.36%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)N/A N/A
Inst Owners69.01%
Inst Owner Change-14.24%
Ins Owners6.83%
Ins Owner Change0.05%
Market Cap694.07M
Analysts41.82
Price Target10.54 (-14.66%)
Short Float %19.39%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.25%
Min EPS beat(2)6.02%
Max EPS beat(2)30.48%
EPS beat(4)3
Avg EPS beat(4)22.63%
Min EPS beat(4)-11.88%
Max EPS beat(4)65.88%
EPS beat(8)5
Avg EPS beat(8)1.14%
EPS beat(12)6
Avg EPS beat(12)0.21%
EPS beat(16)6
Avg EPS beat(16)-243.94%
Revenue beat(2)2
Avg Revenue beat(2)20.83%
Min Revenue beat(2)18.03%
Max Revenue beat(2)23.63%
Revenue beat(4)3
Avg Revenue beat(4)33.8%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)95.92%
Revenue beat(8)5
Avg Revenue beat(8)17.62%
Revenue beat(12)9
Avg Revenue beat(12)15.21%
Revenue beat(16)13
Avg Revenue beat(16)27.99%
PT rev (1m)19.23%
PT rev (3m)24.5%
EPS NQ rev (1m)12.65%
EPS NQ rev (3m)27.03%
EPS NY rev (1m)13.49%
EPS NY rev (3m)16.62%
Revenue NQ rev (1m)-11.6%
Revenue NQ rev (3m)-20.02%
Revenue NY rev (1m)-0.43%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.01
P/FCF N/A
P/OCF N/A
P/B 1.13
P/tB 1.27
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-4.88
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS4.11
BVpS10.91
TBVpS9.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.6%
ROE -51.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.99%
FCFM N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score5
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.99%
Cap/Sales 15.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.41
Quick Ratio 5.41
Altman-Z -6.35
F-Score5
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
EPS Next Y40.12%
EPS Next 2Y20.9%
EPS Next 3Y17.78%
EPS Next 5Y14.86%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%
Revenue Next Year-22.09%
Revenue Next 2Y-5.87%
Revenue Next 3Y-0.63%
Revenue Next 5Y46.59%
EBIT growth 1Y42.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.02%
EBIT Next 3Y19.17%
EBIT Next 5Y41.47%
FCF growth 1Y25.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.97%
OCF growth 3YN/A
OCF growth 5YN/A